{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:05:00Z","timestamp":1777633500016,"version":"3.51.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-026-04086-8","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:39:09Z","timestamp":1777437549000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Efficacy and Safety of Recombinant Human Nerve Growth Factor (rhNGF) in Patients With Dry Eye Disease: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"46","author":[{"given":"Mohammed F.","family":"Qutub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Talal S.","family":"Alajmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed N.","family":"Alnabihi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anas","family":"Alamoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma H.","family":"Almarwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzan E.","family":"Ageel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baraa S.","family":"Tabbakh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama N.","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"issue":"3","key":"4086_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"JP Craig","year":"2017","unstructured":"Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F (2017) TFOS DEWS II definition and classification report. Ocul Surf 15(3):276\u2013283. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.008","journal-title":"Ocul Surf"},{"issue":"3","key":"4086_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","volume":"15","author":"AJ Bron","year":"2017","unstructured":"Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, Knop E, Markoulli M, Ogawa Y, Perez V, Uchino Y (2017) TFOS DEWS II pathophysiology report. Ocul Surf 15(3):438\u2013510. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.011","journal-title":"Ocul Surf"},{"issue":"3","key":"4086_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","volume":"15","author":"L Jones","year":"2017","unstructured":"Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, Dong PN, Geerling G, Hida RY, Liu Y, Seo KY (2017) TFOS DEWS II management and therapy report. Ocul Surf 15(3):575\u2013628. https:\/\/doi.org\/10.1016\/j.jtos.2017.05.006","journal-title":"Ocul Surf"},{"issue":"11","key":"4086_CR4","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.1167\/iovs.03-0270","volume":"44","author":"CG Begley","year":"2003","unstructured":"Begley CG, Chalmers RL, Abetz L, Venkataraman K, Mertzanis P, Caffery BA, Snyder C, Edrington T, Nelson D, Simpson T (2003) The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 44(11):4753\u20134761. https:\/\/doi.org\/10.1167\/iovs.03-0270","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"4086_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/OPTH.S213664","volume":"3","author":"K Stonecipher","year":"2020","unstructured":"Stonecipher K, Komm C, Potvin R (2020) Low level light therapy as an adjunct treatment for meibomian gland dysfunction. Acta Sci Ophthalmol 3(11):13\u201318. https:\/\/doi.org\/10.2147\/OPTH.S213664","journal-title":"Acta Sci Ophthalmol"},{"issue":"3","key":"4086_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1097\/ICU.0000000000000569","volume":"30","author":"EC O\u2019Neil","year":"2019","unstructured":"O\u2019Neil EC, Henderson M, Massaro-Giordano M, Bunya VY (2019) Advances in dry eye disease treatment. Curr Opin Ophthalmol 30(3):166\u2013178. https:\/\/doi.org\/10.1097\/ICU.0000000000000569","journal-title":"Curr Opin Ophthalmol"},{"issue":"8","key":"4086_CR7","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1167\/iovs.03-0037","volume":"44","author":"E Ghinelli","year":"2003","unstructured":"Ghinelli E, Johansson J, R\u00edos JD, Chen LL, Zoukhri D, Hodges RR, Dartt DA (2003) Presence and localization of neurotrophins and neurotrophin receptors in rat lacrimal gland. Invest Ophthalmol Vis Sci 44(8):3352\u20133357. https:\/\/doi.org\/10.1167\/iovs.03-0037","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"4086_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/aos.13844","volume":"97","author":"M Labetoulle","year":"2019","unstructured":"Labetoulle M, Baudouin C, Calonge M, Merayo\u2010Lloves J, Boboridis KG, Akova YA, Aragona P, Geerling G, Messmer EM, Ben\u00edtez\u2010del\u2010Castillo J (2019) Role of corneal nerves in ocular surface homeostasis and disease. Acta Ophthalmol 97(2):137\u2013145. https:\/\/doi.org\/10.1111\/aos.13844","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"4086_CR9","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1167\/iovs.16-21372","volume":"58","author":"G Di","year":"2017","unstructured":"Di G, Qi X, Zhao X, Zhang S, Danielson P, Zhou Q (2017) Corneal epithelium-derived neurotrophic factors promote nerve regeneration. Invest Ophthalmol Vis Sci 58(11):4695\u20134702. https:\/\/doi.org\/10.1167\/iovs.16-21372","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"4086_CR10","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0014-4835(03)00050-2","volume":"76","author":"LJ M\u00fcller","year":"2003","unstructured":"M\u00fcller LJ, Marfurt CF, Kruse F, Tervo TM (2003) Corneal nerves: structure, contents and function. Exp Eye Res 76(5):521\u2013542. https:\/\/doi.org\/10.1016\/S0014-4835(03)00050-2","journal-title":"Exp Eye Res"},{"issue":"1","key":"4086_CR11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1136\/bjophthalmol-2018-312470","volume":"104","author":"M Sacchetti","year":"2020","unstructured":"Sacchetti M, Lambiase A, Schmidl D, Schmetterer L, Ferrari M, Mantelli F, Allegretti M, Garhoefer G (2020) Effect of recombinant human nerve growth factor eye drops in patients with dry eye: a phase IIa, open label, multiple-dose study. Br J Ophthalmol 104(1):127\u2013135. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-312470","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"4086_CR12","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12886-024-03564-w","volume":"24","author":"D Wirta","year":"2024","unstructured":"Wirta D, Lipsky W, Toyos M, Martel J, Goosey J, Verachtert A, El-Harazi S, Karpecki P, Allegretti M, Goisis G, Pasedis G (2024) Recombinant human nerve growth factor (cenegermin) for moderate-to-severe dry eye: phase II, randomized, vehicle-controlled, dose-ranging trial. BMC Ophthalmol 24(1):290. https:\/\/doi.org\/10.1186\/s12886-024-03564-w","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"4086_CR13","doi-asserted-by":"publisher","first-page":"e1230","DOI":"10.1002\/cl2.1230","volume":"18","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: an R package and Shiny app for producing PRISMA 2020\u2010compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev 18(2):e1230. https:\/\/doi.org\/10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"issue":"1","key":"4086_CR14","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"4086_CR15","doi-asserted-by":"publisher","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR 2019 RoB 2: a revised tool for assessing risk of bias in randomised trials. bmj. 366 https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"4086_CR16","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier\u202fNCT05133180, A 4-week, Phase\u202fIII, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate\u00ae (cenegermin 20\u202f\u00b5g\/mL ophthalmic solution) versus vehicle in severe Sj\u00f6gren\u2019s dry eye disease; [cited 2025 Jul\u202f30]. Available from:\u00a0https:\/\/clinicaltrials.gov\/study\/NCT05133180."},{"key":"4086_CR17","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier\u202fNCT05136170, A phase iii randomized, double-blind, placebo-controlled study of cenegermin ophthalmic solution in adults with severe sj\u00f6gren\u2019s-related dry eye disease; [cited 2025 Jul 30]. Available from:\u00a0https:\/\/clinicaltrials.gov\/study\/NCT05136170."},{"key":"4086_CR18","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Identifier NCT03019627, An 8-week, Phase\u202fII, single-center, randomized, double-masked, vehicle-controlled, parallel-group study with 4 weeks of follow-up to evaluate safety and efficacy of rhNGF eye drops solution versus vehicle in patients with dry eye; [cited 2025 Jul 30]. Available from:\u00a0https:\/\/clinicaltrials.gov\/study\/NCT03019627."},{"key":"4086_CR19","doi-asserted-by":"publisher","first-page":"826530","DOI":"10.3389\/fmed.2021.826530","volume":"8","author":"Y Wu","year":"2022","unstructured":"Wu Y, Wang C, Wang X, Mou Y, Yuan K, Huang X et al (2022) Advances in dry eye disease examination techniques. Front Med 8:826530. https:\/\/doi.org\/10.3389\/fmed.2021.826530","journal-title":"Front Med"},{"issue":"9","key":"4086_CR20","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1016\/j.ophtha.2019.03.050","volume":"126","author":"DF Goldberg","year":"2019","unstructured":"Goldberg DF, Malhotra RP, Schechter BA, Justice A, Weiss SL, Sheppard JD (2019) A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease. Ophthalmology 126(9):1230\u20131237. https:\/\/doi.org\/10.1016\/j.ophtha.2019.03.050","journal-title":"Ophthalmology"},{"issue":"8","key":"4086_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1089\/jop.2020.0180","volume":"37","author":"KK Nichols","year":"2021","unstructured":"Nichols KK, Donnenfeld ED, Karpecki PM, Thoen R, Holland EJ (2021) A comprehensive review of the clinical trials conducted for dry eye disease and the impact of the vehicle comparators in these trials. J Ocul Pharmacol Ther 37(8):457\u2013472. https:\/\/doi.org\/10.1089\/jop.2020.0180","journal-title":"J Ocul Pharmacol Ther"},{"key":"4086_CR22","doi-asserted-by":"publisher","first-page":"108428","DOI":"10.1016\/j.exer.2020.108428","volume":"203","author":"Q Gong","year":"2021","unstructured":"Gong Q, Zhang S, Jiang L, Lin M, Xu Z, Yu Y, Wang Q, Lu F, Hu L (2021) The effect of nerve growth factor on corneal nerve regeneration and dry eye after LASIK. Exp Eye Res 203:108428. https:\/\/doi.org\/10.1016\/j.exer.2020.108428","journal-title":"Exp Eye Res"},{"issue":"11","key":"4086_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.18240\/ijo.2021.11.02","volume":"14","author":"LQ Wan","year":"2021","unstructured":"Wan LQ, Zhang YY, Wang HF, Chen C, Li H, Zhang Y, Xue JF, Zhou QJ, Xie LX (2021) Efficacy of rhNGF-loaded amniotic membrane transplantation for rabbit corneal epithelial and nerve regeneration. Int J Ophthalmol 14(11):1653. https:\/\/doi.org\/10.18240\/ijo.2021.11.02","journal-title":"Int J Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04086-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-026-04086-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-026-04086-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T04:39:22Z","timestamp":1777437562000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-026-04086-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4086"],"URL":"https:\/\/doi.org\/10.1007\/s10792-026-04086-8","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.\n                      Ethical aproaval\n                      Ethical review and approval were waived for this study, as it is a systematic review and meta-analysis that used data from previously published studies. No new data involving human participants or animals were collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"216"}}